TransMedics Group (TMDX) has received a new Buy rating, initiated by Evercore ISI analyst, Daniel Markowitz CFA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Markowitz CFA has given his Buy rating due to a combination of factors that highlight TransMedics Group’s promising financial and operational outlook. The company offers a unique, comprehensive organ transplant service that integrates advanced technology and logistics, which is expected to drive significant growth. Despite initial perceptions of higher costs, the total expenses for TransMedics’ services are comparable to alternatives, while delivering superior patient outcomes and operational efficiencies.
TransMedics is poised for substantial growth, with projections indicating a revenue compound annual growth rate of over 20% and an earnings per share growth rate of approximately 50% from 2025 to 2028. The company’s innovative approach and expansion plans, including entering new markets and increasing organ utilization rates, support the optimistic outlook. These factors contribute to the Buy rating and a target price of $155, suggesting a potential upside of around 35%.
In another report released on September 12, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $131.00 price target.